【 Right now’s Headlines 】
“Stablecoin Regulation” Formally Turns into Regulation, Alternatives Come up within the RWA Sector
The Hong Kong Particular Administrative Area authorities printed the “Stablecoin Regulation” within the gazette on Could 30, signifying that the regulation has formally develop into legislation. Beforehand, the Hong Kong Legislative Council had formally handed the draft regulation on Could 21, establishing a licensing system for “fiat-backed stablecoin” issuers in Hong Kong. The legislation goals to advertise monetary innovation whereas sustaining monetary stability and marks an essential step for Hong Kong within the digital asset sector. Ding Zhaofei, Chief Analyst at HashKey Group, acknowledged that the official launch of the “Stablecoin Regulation” is a big milestone in Hong Kong’s digital asset regulatory course of.
CITIC Securities analysis report indicated that on Could 30, Hong Kong’s “Stablecoin Regulation” turned the world’s first specialised laws focusing on fiat-backed stablecoins, successfully filling the regulatory hole for fiat-backed stablecoins and accelerating the compliant improvement of stablecoins. As RWA continues to deepen and develop, issuing establishments, custodial banks, buyers, and blockchain entities inside the RWA ecosystem are anticipated to develop quickly, doubtlessly bringing funding alternatives in areas akin to RWA asset operations, banking IT, and cross-border funds. It is strongly recommended to concentrate to: stablecoin issuers and cryptocurrency exchanges that can profit straight; contemplating RWA as a beneficiary within the crypto market, it’s urged to deal with service suppliers able to issuing RWA, particularly these associated to Ant Group which have already efficiently run RWA issuance enterprise; the event of cryptocurrencies and stablecoins in Hong Kong will considerably promote the internationalization of the Renminbi and cross-border funds, so it’s advisable to concentrate to cross-border payment-related entities.
【Market Outlook】
Spot gold rises 2.79%, reported at $3,380.84 per ounce
In a single day, the Dow Jones Industrial Common closed up barely by 35.41 factors, a rise of 0.08%, closing at 42,305.48 factors; the Nasdaq rose by 128.85 factors, a rise of 0.67%, closing at 19,242.61 factors; the S&P 500 index rose by 24.25 factors, a rise of 0.41%, closing at 5,935.94 factors. NVIDIA (NVDA.US) rose by 1.6%, Macy’s (M.US) fell almost 5%, and AMD (AMD.US) rose by 3.5%. The Nasdaq Golden Dragon China Index closed up 0.5%, with Alibaba (BABA.US) rising by 0.8%. The Grasp Seng Index ADR rose, closing at 23,242.11 factors, a rise of 84.14 factors or 0.36% in comparison with the Hong Kong shut.
Spot gold rose 2.79%, reported at $3,380.84 per ounce, remaining in an upward pattern all through the day.
【Scorching Subjects Forward】
Worldwide Oil Costs Proceed to Rise
On account of geopolitical tensions, worldwide oil costs expanded their good points throughout the day. Mild crude oil futures for July supply on the New York Mercantile Alternate rose by $1.73, closing at $62.52 per barrel, a rise of two.85%; August supply Brent crude oil futures rose by $1.85, closing at $64.63 per barrel, a rise of two.95%. Following Ukraine’s drone assaults deep into Russian territory, elevating the potential for oil provide disruptions, oil costs surged right now
Morgan Stanley analysts acknowledged in a report that the assaults have offset OPEC+’s improve of 411,000 barrels per day in July. The analysts talked about that because the provide improve aligns with market expectations, oil costs are unlikely to be affected within the quick time period. Nonetheless, the outlook for an oil surplus by the top of 2025 stays unchanged. Morgan Stanley added that attributable to no indicators of a slowdown in OPEC+’s quota will increase, Brent crude oil costs might commerce round $50 per barrel within the first half of 2026.
Elevated Flights on China-US Routes Delta Restarts Direct Flights from Shanghai to Los Angeles
Delta Air Traces formally resumed direct flights from Shanghai Pudong Worldwide Airport to Los Angeles Worldwide Airport on June 2, working three flights per week. Because of this, Delta will function a complete of 17 direct flights between China and the US every week, involving the aviation sector.
2025 Dragon Boat Pageant Field Workplace Up 20% Yr-on-Yr
In line with Lighthouse Skilled Version, as of June 2 at 21:00, the field workplace for the 2025 Dragon Boat Pageant reached 459 million, a 20% improve in comparison with the 2024 Dragon Boat Pageant field workplace. “Mission: Inconceivable 8 – Useless Reckoning” grossed 190 million throughout the identical interval, securing the field workplace champion for the 2025 Dragon Boat Pageant.
China’s Implantable Mind-Machine Interface Begins Scientific Enrollment Thousands and thousands of Spinal Damage Sufferers See Hope
Just lately, on the twentieth Asian Neuro-Oncology Annual Assembly held in Shanghai, Professor Mao Ying, director of Huashan Hospital affiliated with Fudan College, revealed {that a} medical cohort research on brain-machine interfaces led by Huashan Hospital and Beijing Xuanwu Hospital has begun affected person enrollment, aiming to additional confirm the effectiveness and security of the implantable brain-machine interface therapy plan. Moreover, it was introduced on the assembly that Shanghai will set up knowledgeable subcommittee on brain-machine interfaces and neural regulation, gathering a number of forces from the “industry-academia-research-medical” innovation chain to attain breakthroughs in authentic know-how. The yr 2025 is a key yr for China’s brain-machine interface know-how to formally enter medical observe. Beforehand, cities like Beijing and Shanghai have issued associated industrial plans for brain-machine interfaces, with plans to finish medical trials for greater than 5 invasive merchandise by 2030.
Ocean Park (02255) Plans to Subject 5.1 Billion Shares at a Low cost of Roughly 46.43%, Netting About HKD 2.284 Billion
In line with Zhitong Finance APP, Ocean Park (02255) introduced that on June 2, 2025, the corporate entered right into a subscription settlement with the subscriber (Xiangyuan Xinghai Tourism (Cayman) Co., Ltd.) and Xiangyuan, proposing to difficulty 5.1 billion new shares, equal to 38.60% of the corporate’s enlarged issued share capital after the issuance. The subscription worth is HKD 0.45 per share, representing a reduction of roughly 46.43% in comparison with the closing worth of HKD 0.8400 per share on June 2.
Xinda Vehicle Completes Subscription of Zhengtong Vehicle (01728) 6.669 Billion Shares, Holding Ratio Reaches 75%
In line with Zhitong Finance APP, Zhengtong Vehicle (01728) and the offeror Xinda Vehicle (Hong Kong) Co., Ltd. collectively introduced that the associated subscription matter was accomplished on June 2, 2025. In line with the associated subscription matter, the corporate issued and allotted shares at a subscription worth of HKD 0.15 per share, and the offeror subscribed for six.669 billion shares, with a complete money consideration of HKD 1 billion. The subscribed shares account for roughly 66.58% of the issued shares as of the date of this joint announcement
Hansoh Pharmaceutical (03692) Grants Regeneron Unique Abroad License for GLP-1/GIP Twin Receptor Agonist HS-20094
Hansoh Pharmaceutical introduced that it has entered right into a licensing settlement with Regeneron Prescribed drugs, Inc.*, granting Regeneron international unique rights to develop, manufacture, and commercialize HS-20094. Beneath the settlement, Hansoh Pharmaceutical will obtain an upfront cost of $80 million and is eligible to obtain as much as $1.93 billion in milestone funds based mostly on the product’s improvement, registration approval, and commercialization progress, in addition to a double-digit share royalty on future potential product gross sales.
Longpan Expertise (02465): Subsidiary Indicators Lengthy-term Settlement with Eve Vitality’s Affiliate, Anticipated Gross sales of 152,000 Tons of Lithium Iron Phosphate, Amounting to Over 5 Billion Yuan
In line with Zhitong Finance APP, Longpan Expertise (02465) introduced that its controlling subsidiary LBM NEW ENERGY (AP) PTE. LTD. (hereinafter known as “Lithium Supply (Asia Pacific)”) has signed a Manufacturing Pricing Settlement (hereinafter known as “Settlement”) with Eve Vitality Malaysia Sdn. Bhd. (hereinafter known as “Eve Vitality”). The settlement stipulates that Lithium Supply (Asia Pacific) and its associates (hereinafter known as “Vendor”) are anticipated to promote a complete of 152,000 tons of lithium iron phosphate cathode supplies that meet the specs agreed upon by each events to Eve Vitality and its associates (hereinafter known as “Purchaser”) from 2026 to 2030. The Purchaser is allowed to regulate the anticipated demand inside a sure vary, supplied that the advance discover interval is met. The particular unit worth shall be decided by each events on a quarterly foundation in response to the phrases of this settlement. Based mostly on the estimated amount and market worth, the whole contract gross sales quantity exceeds 5 billion yuan (remaining settlement based mostly on precise gross sales orders), reaching the disclosure requirements set by the Shanghai Stock Alternate Itemizing Guidelines.
[Stock Highlights]
Shiyao Group (01093): JMT101 Receives Breakthrough Remedy Designation in China for the Remedy of Colorectal Most cancers
Shiyao Group (01093) introduced that its developed JMT101 has lately obtained breakthrough remedy designation from the Nationwide Medical Merchandise Administration of the Individuals’s Republic of China, indicated to be used together with Irinotecan for the therapy of superior colorectal most cancers with RAS, RAF, EGFR ECD, and PIK3CA exon 20 wild-type that has failed second-line or above commonplace therapy. Colorectal most cancers is the third commonest most cancers globally, with 517,000 new circumstances and 240,000 deaths reported in China in 2022, rating second and fourth respectively in new malignant tumor circumstances and deaths.
The announcement talked about that JMT101 together with Irinotecan has proven important efficacy in an ongoing randomized, managed, open-label Section II research. The outcomes indicated that the median progression-free survival (mPFS) for the JMT101 plus Irinotecan group was 7.4 months, considerably larger than the two.9 months noticed within the management group. Moreover, JMT101 has proven good advantages in each beforehand handled and untreated EGFR populations
Based mostly on good efficacy and security knowledge, the breakthrough remedy designation for JMT101 will assist speed up its improvement course of, which has now superior to the vital Section III medical trials, and a number of medical research focusing on different cancers are being carried out in China
